- Home
- INO vs RPTX Comparison
INO vs RPTX Comparison
Compare INO & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- RPTX
- Stock Information
- Founded
- INO 1979
- RPTX 2016
- Country
- INO United States
- RPTX Canada
- Employees
- INO N/A
- RPTX N/A
- Industry
- INO Medical/Dental Instruments
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- INO Health Care
- RPTX Health Care
- Exchange
- INO Nasdaq
- RPTX Nasdaq
- Market Cap
- INO 69.3M
- RPTX 64.8M
- IPO Year
- INO 1998
- RPTX 2020
- Fundamental
- Price
- INO $1.96
- RPTX $1.59
- Analyst Decision
- INO Buy
- RPTX Strong Buy
- Analyst Count
- INO 5
- RPTX 3
- Target Price
- INO $8.80
- RPTX $4.50
- AVG Volume (30 Days)
- INO 1.9M
- RPTX 86.2K
- Earning Date
- INO 08-12-2025
- RPTX 08-08-2025
- Dividend Yield
- INO N/A
- RPTX N/A
- EPS Growth
- INO N/A
- RPTX N/A
- EPS
- INO N/A
- RPTX N/A
- Revenue
- INO $182,337.00
- RPTX $250,000.00
- Revenue This Year
- INO N/A
- RPTX N/A
- Revenue Next Year
- INO $20,588.06
- RPTX N/A
- P/E Ratio
- INO N/A
- RPTX N/A
- Revenue Growth
- INO N/A
- RPTX N/A
- 52 Week Low
- INO $1.30
- RPTX $0.89
- 52 Week High
- INO $7.76
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- INO 66.94
- RPTX 59.76
- Support Level
- INO $1.80
- RPTX $1.54
- Resistance Level
- INO $2.08
- RPTX $1.60
- Average True Range (ATR)
- INO 0.12
- RPTX 0.04
- MACD
- INO 0.06
- RPTX -0.00
- Stochastic Oscillator
- INO 82.35
- RPTX 84.62
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.